Another Adalimumab Biosimilar Seems Set for Interchangeability

(MedPage Today) -- PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving nearly 445 rheumatoid arthritis...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news